Statins are among the most prescribed medications in the world, but they aren’t the right choice for everyone. Somewhere between 5% and 25% of people on statins report muscle symptoms, and the drugs carry a measurable increase in diabetes risk. Beyond side effects, the benefit of statins depends heavily on your individual heart disease risk, meaning some people take them when the payoff is genuinely small. Here are the specific reasons people avoid statins, what the evidence actually shows, and what the alternatives look like.
Muscle Pain and Weakness
Muscle symptoms are the most common reason people stop taking statins. These range from mild aching and stiffness to, rarely, serious muscle breakdown. In clinical studies, about 10% to 12% of statin users report muscle pain, though surveys of former users put the number much higher. The tricky part: in blinded trials where neither the patient nor the doctor knows who’s getting the real drug, people on placebo pills report muscle pain at nearly identical rates (12.4% vs. 12.7%). This suggests that some portion of statin-related muscle complaints are driven by expectation rather than the drug itself.
That said, real statin-triggered muscle problems do exist. They tend to show up within weeks to months of starting the medication, and they resolve when the drug is stopped. Risk factors include higher doses, older age, smaller body size, kidney problems, and taking certain other medications that interact with statins. In extremely rare cases (roughly 1 in 10,000 users per year), statins cause rhabdomyolysis, a severe breakdown of muscle tissue that can damage the kidneys.
Increased Risk of Type 2 Diabetes
Statins raise blood sugar. A large meta-analysis of randomized trials found that low-to-moderate dose statins increased the rate of new diabetes diagnoses by 10%, while high-dose statins increased it by 36%. This effect is most relevant if you already have prediabetes or other risk factors for diabetes, such as obesity or a family history. For someone whose blood sugar is already borderline, a statin can tip it over the diagnostic threshold.
This doesn’t mean statins cause diabetes out of nowhere in otherwise healthy people. The risk is concentrated in those already trending in that direction. Still, if you’re in that group, the tradeoff between heart protection and metabolic harm deserves a real conversation, not just a default prescription.
When the Benefit Is Too Small to Justify
The strongest case for statins exists in people who already have heart disease or who face a high probability of a heart attack or stroke in the next decade. For people at lower risk, the math changes considerably.
The U.S. Preventive Services Task Force acknowledges that for adults with an estimated 10-year cardiovascular risk between 7.5% and 10%, statins offer “at least a small net benefit,” and the decision should depend on individual preference for that small benefit weighed against the potential harms and inconvenience of daily medication. Below that risk threshold, major guidelines don’t recommend routine statin use at all. The higher your baseline risk, the more likely a statin will actually prevent something. For a healthy 45-year-old with mildly elevated cholesterol and no other risk factors, the absolute chance of preventing a heart attack over 5 to 10 years of daily pills can be quite low.
This is where the concept of “number needed to treat” matters. In low-risk populations, dozens of people may need to take a statin for years so that one person avoids a cardiovascular event. The rest get no measurable benefit but still face the side effects.
Liver Effects
Statins can cause liver enzyme elevations, which historically led to routine blood monitoring. An analysis of the FDA’s adverse event database found that all seven marketed statins have been linked to liver-related reports, with the most common being elevated liver enzymes and abnormal liver function tests. However, clinically significant liver damage from statins is rare, and the overall fatality rate from statin-related liver problems is low. Simvastatin has shown the highest correlation with serious liver toxicity among the available statins.
People with active liver disease or unexplained persistent elevations in liver enzymes are generally not candidates for statin therapy. If you have a history of liver problems, this is a legitimate reason to explore other options.
Cognitive Concerns
Reports of memory loss and mental fogginess while on statins prompted the FDA to add a label warning in 2012. This concern is widespread enough that cognitive changes are the second most frequently reported statin side effect. However, the longest and most rigorous studies have not confirmed a link. A six-year study of community-dwelling older Australians found no difference in the rate of memory decline or brain volume changes between statin users and non-users.
The disconnect likely comes from individual case reports and the fact that many statin users are older adults who may experience age-related cognitive changes regardless of medication. Some people do report a subjective sense of mental cloudiness that clears when they stop the drug, and that experience is real even if large studies can’t detect a population-level effect.
Age Over 75
Guidelines become notably cautious about statins in older adults. The ACC/AHA guidelines recommend individualizing the decision to start statins for primary prevention in adults over 75, and the European guidelines for patients over 80 cite insufficient evidence to make a firm recommendation. Most of the major clinical trials that proved statins work enrolled few patients over 75 and essentially none over 80.
For older adults who have never had a heart attack or stroke, the potential benefit of starting a statin shrinks as competing health concerns, limited life expectancy, and the cumulative burden of multiple medications come into play. In very old patients, providers and patients may jointly decide to lower the dose or stop entirely. For secondary prevention (meaning after a heart attack or stroke), moderate-dose statins still appear beneficial regardless of age.
Breastfeeding
If you’re breastfeeding, statins are not recommended. The drugs can pass into breast milk and pose a risk to the infant. Many people can safely pause their statin until breastfeeding ends. For those who need ongoing treatment due to high cardiovascular risk, the FDA advises using formula or other alternatives rather than breastfeeding while on the medication.
Interestingly, the FDA recently removed its strongest warning against statin use during pregnancy itself, acknowledging that the previous blanket contraindication was overly broad. But the breastfeeding restriction remains in place.
What Statin Intolerance Looks Like
Statin intolerance has a formal definition: you experience side effects that resolve when you stop the drug or lower the dose, and this has happened with at least two different statins, including one at the lowest available dose. Intolerance can be complete (you can’t tolerate any statin at any dose) or partial (you can handle a lower dose, but not enough to reach your cholesterol target).
If you’ve only tried one statin and had problems, that alone doesn’t qualify as true intolerance. Doctors will typically suggest trying a different statin, a lower dose, or a non-daily dosing schedule using one of the longer-acting statins before concluding that statins simply won’t work for you. Holding the medication until symptoms clear, then restarting at a lower dose, can help determine whether the statin was genuinely causing the problem.
Alternatives for People Who Can’t Take Statins
If statins are off the table, several other medications lower cholesterol through different pathways. The options vary widely in how much they reduce LDL cholesterol and how they’re taken.
- Ezetimibe blocks cholesterol absorption in the gut. It lowers LDL by about 18% on its own or 25% when paired with a statin. It’s affordable, well tolerated, and taken as a daily pill.
- Bempedoic acid reduces cholesterol production through a different enzyme than statins, which means it doesn’t cause the same muscle problems. It lowers LDL by 23% to 24% alone and has been shown to reduce cardiovascular events in people with statin intolerance. It can raise uric acid levels, so it’s not ideal if you have gout.
- PCSK9 inhibitors are injectable medications given every two weeks or, in the case of newer formulations, every six months. They’re the most powerful option, lowering LDL by 45% to 64%. They’re typically reserved for high-risk patients who can’t reach their goals with pills alone, partly because of cost.
For people at lower cardiovascular risk who simply prefer to avoid medication altogether, lifestyle changes remain the foundation: dietary shifts that reduce saturated fat intake, regular physical activity, weight management, and smoking cessation. These won’t match the LDL reduction of a high-dose statin, but for someone whose risk is modest to begin with, they may be enough.